MicroRNA-125a-5p Inhibits Invasion and Metastasis of Gastric Cancer Cells by Targeting BRMS1 Expression
Overview
Authors
Affiliations
Accumulating studies have demonstrated microRNAs (miRNAs/miRs) have an important role in multiple processes of human malignant tumor development and progression. Decreased expression of miR-125a-5p has been observed in several types of cancer, including gastric cancer (GC). However, the mechanism and exact function of miR-125a-5p in GC have not been largely elucidated. In the present study, reverse transcription-quantitative polymerase chain reaction indicated that the expression of miR-125a-5p was downregulated in GC tissues and cell lines compared with matched normal tissues (P<0.01) and normal gastric mucosa cell lines (P<0.01), respectively. Moreover, clinical pathological characteristics and Kaplan-Meier analysis indicated that a low expression of miR-125a-5p was not only associated with lymph metastasis, peritoneal dissemination and advanced tumor-node metastasis stage but also affected the prognosis of GC patients. Compared with miR-control-transfected GC cells, markedly decreased migration and invasion was observed in GC cells that overexpress miR-125a-5p. By contrast, increased metastasis and invasion were observed in miR-125a-5p-knocked down cells compared with the control. Furthermore, luciferase reporter assays indicated that breast cancer metastasis suppressor 1 (BRMS1) was a direct target of miR-125a-5p. Notably, a positive correlation between the levels of BRMS1 and miR-125a-5p in GC tissues was observed, and BRMS1 expression was indicated to be regulated by miR-125a-5p in GC cells. In conclusion, miR-125a-5p may act as a tumor suppressor by targeting the metastasis-inhibitory gene, BRMS1. The data suggesting that BRMS1 is a potential target gene of miR-125a-5p, may provide novel insight into miRNA regulation of human gene expression, and a useful target for gene therapy of GC.
The Most Recent Insights into the Roots of Gastric Cancer.
Melit L, Marginean C, Borka Balas R Life (Basel). 2024; 14(1).
PMID: 38255710 PMC: 10817233. DOI: 10.3390/life14010095.
Perez-Duran J, Luna A, Portilla A, Martinez P, Ceballos G, Ortiz-Flores M Molecules. 2023; 28(17).
PMID: 37687058 PMC: 10488497. DOI: 10.3390/molecules28176229.
BRMS1 in Gliomas-An Expression Analysis.
Feldheim J, Kessler A, Feldheim J, Schmitt D, Oster C, Lazaridis L Cancers (Basel). 2023; 15(11).
PMID: 37296870 PMC: 10252102. DOI: 10.3390/cancers15112907.
Galiveti C, Kuhnell D, Biesiada J, Zhang X, Kelsey K, Takiar V Head Neck. 2022; 45(1):212-224.
PMID: 36271833 PMC: 9742186. DOI: 10.1002/hed.27231.
Hatmal M, Al-Hatamleh M, Olaimat A, Alshaer W, Hasan H, Albakri K Biomedicines. 2022; 10(6).
PMID: 35740242 PMC: 9219990. DOI: 10.3390/biomedicines10061219.